AstraZeneca (NYSE: AZN ) and GlaxoSmithKline (NYSE: GSK ) have a lot of work ahead. Both are struggling to find revenue to replace sales from aging blockbusters (Nexium and Crestor for AstraZeneca and Advair for GlaxoSmithKline), although both also have some exciting pipeline prospects that may cushion that blow. Both also pay strong dividends, which may make them an intriguing play for income investors.
So, when comparing the two British pharmas, which is the better buy?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson answer.
An even better investment opportunity?
Let's face it -- the best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.